Solid forms of TYK2 inhibitors, methods of preparation, and uses thereof

JP2024544245AInactive Publication Date: 2024-11-28BEIGENE SWITZERLAND GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534436
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-02
Filing Date
2022-12-22
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0006】 本開示の発明者らは、(形態A、B、C、及びD)を含む、化合物1の4つの結晶形態を予想外に発見し、化合物1形態Aは、良好な物理化学的安定性を有する。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544245000034
    Figure 2024544245000034
  • Figure 2024544245000035
    Figure 2024544245000035
  • Figure 2024544245000036
    Figure 2024544245000036
Patent Text Reader

Abstract

Disclosed herein are solid forms of the TYK2 inhibitor N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide per se and pharma- ceutically acceptable salts of the TYK2 inhibitor or crystalline forms of said salts, pharmaceutical compositions comprising said crystalline forms or said salts or said salts of said crystalline forms, processes for preparing said crystalline forms or said salts or said salts of said crystalline forms, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Disclosed herein are solid forms of the TYK2 inhibitor N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide per se and pharma- ceutically acceptable salts of the TYK2 inhibitor or crystalline forms of said salts, pharmaceutical compositions comprising said crystalline forms or said salts or said salts of said crystalline forms, processes for preparing said crystalline forms or said salts or said salts of said crystalline forms, and methods of use thereof. [Background technology]

[0002] The Janus kinase family, which includes JAK1, JAK2, JAK3, and tyrosine kinase 2 (Tyk2), are non-receptor tyrosine kinases that bind to the intracellular portions of cell surface cytokine receptors. In response to stimulation of these receptors, Janus kinases phosphorylate signal transducers and activators of transcription (STAT) proteins, which then dimerize, translocate to the nucleus, and activate gene transcription. Tyrosine kinase 2 (Tyk2) is a member of the Janus kinase (JAK) family of non-receptor tyrosine kinases and has been reported in mice (Ishizaki,M.et al.,“Involvement of Tyrosine Kinase-2 in Both the IL-12 / TH1 and IL-23 / TH17 Axes in vivo”,J.Immunol.,187:181-189(2011); Prchal-Murphyl,M.et al.,“TYK2 kinase activity is required for functional type I interferon responses in vivo”,PloS one,7:e39141 (2012)) and humans (Minegishi,Y.et al.,“Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate acquired Tyk2 has been shown to be crucial in regulating signaling cascades downstream of the receptors for IL-12, IL-23, and type I interferons in both the IL-12 and IL-23 T cell lines (Tyk2 T cell line, Immunity, 25:745-755 (2006)). Tyk2 mediates receptor-induced phosphorylation of members of the STAT family of transcription factors, which is an essential signal that leads to dimerization of STAT proteins and transcription of STAT-dependent proinflammatory genes.Tyk2-deficient mice are resistant to experimental models of colitis, psoriasis, and multiple sclerosis, demonstrating the importance of Tyk2-mediated signaling in autoimmune and related disorders (Ishizaki, M. et al., "Involvement of Tyrosine Kinase-2 in Both the IL-12 / TH1 and IL-23 / TH17 Axes in vivo", J.Immunol., 187:181-189 (2011); Oyamada, A. et al., "Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis", J.Immunol., 2009, 183, 7539-7546).

[0003] To date, most of the known small molecule JAK inhibitors that have reached development are active site-specific inhibitors that bind to the adenosine triphosphate (ATP) site of the catalytic domain of the JAK protein (also referred to as the JH1 or "Janus homolog 1" domain), which prevents the catalytic activity of the kinase by blocking ATP, downstream phosphorylation, and the resulting pathway signaling (Bryan, M. et al., "Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances", J. Med. Chem. 2018, 61, 9030-9058). JAK2 is involved in hematopoiesis (Neubauer, H.; et al., "JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis", Cell 1998, 93, 397-409), and inhibition of JAK2 may cause side effects such as anemia, neutropenia, and increased risk of infection and lipid abnormalities (Wollenhaupt, J., et al., "Safety and efficacy of tofacitinib, an oral Janus Kinase Inhibitor, for the treatment of rheumatoid arthritis in open-label. J. Rheumatol. 2014, 41, 837-852, He, Y., et al., Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet. Disord. 2013, 14, 298, Zerbini, CA, et al., Tofacitinib for the treatment of rheumatoid arthritis.Expert Rev.Clin.Immunol.2012,8,319-331).

[0004] N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide (Compound 1) is a TYK2 inhibitor described in unpublished PCT application PCT / CN2021 / 101282. There is a great need to find a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, that can provide good stability and good manufacturability suitable for pharmaceutical formulation. The present disclosure advantageously meets one or more of these requirements. Summary of the Invention [Problem to be solved by the invention]

[0005] The present disclosure addresses the aforementioned problems and needs by providing solid forms, particularly the crystalline forms of Compound 1 itself or a pharma- ceutically acceptable salt of Compound 1 or a pharma- ceutically acceptable salt of the crystalline forms, that are suitable for pharmaceutical use. [Means for solving the problem]

[0006] The inventors of the present disclosure have unexpectedly discovered four crystalline forms of Compound 1, including (Forms A, B, C, and D), with Compound 1 Form A having good physicochemical stability.

[0007] The inventors of the present disclosure have also found salts of Compound 1, namely, hydrochloride, sulfate, phosphate, maleate, fumarate, HBr, mesylate, and esylate salts. In particular, the inventors have found crystalline forms of salts of Compound 1, including crystalline forms of the hydrochloride salt (forms B, C, and D), crystalline forms of the sulfate salt (forms A and B), crystalline forms of the phosphate salt Form A, crystalline forms of the maleate salt Form A, crystalline forms of the fumarate salt (forms A and B), crystalline forms of the HBr salt Form A, crystalline forms of the mesylate salt (forms A, B, and C), and crystalline forms of the esylate salt (forms A and B).

[0008] Among the crystalline forms of Compound 1, Compound 1 mesylate Form C, phosphate Form A, maleate Form A, fumarate Form B, and hydrochloride Form C and hydrochloride Form D are physically and chemically stable for one week at 25° C. / 60% RH or 40° C. / 75% RH, and some forms are physically and chemically stable in a closed container for six months at 25° C. / 60% RH, 30° C. / 65% RH, or 40° C. / 75% RH.

[0009] Compound 1 mesylate Form C, phosphate Form A, maleate Form A, and hydrochloride Form C are slightly hygroscopic, and Compound 1 hydrochloride Form D is non-hygroscopic. In addition, the crystalline forms including Compound 1 mesylate, phosphate Form A, maleate Form A, hydrochloride Form C, and hydrochloride Form D derived from C exhibited good resistance to compression, dry grinding, and granulation simulation without morphological changes and showed no obvious loss of crystallinity, and Compound 1 hydrochloride Form C exhibited good resistance to compression without morphological changes and showed no obvious loss of crystallinity, but the XRPD peaks were slightly broadened when compressed at 5 MPa, 10 MPa, and 20 MPa.

[0010] In addition, some crystalline forms, such as Compound 1 mesylate Form C, phosphate Form A, maleate Form A, or fumarate Form B, exhibit relatively high solubility and good PK exposure in some solvent systems.

[0011] In a first aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, which is designated as Compound 1 Form A (i.e., the crystalline form of Compound 1 itself).

[0012] In some embodiments, Compound 1 Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 10.3±0.2°, 14.8±0.2°, and 16.2°±0.2°.

[0013] In some embodiments, Compound 1 Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 10.3±0.2°, 14.8±0.2°, 16.2±0.2°, 20.7±0.2°, and 21.6±0.2°.

[0014] In some embodiments, Compound 1 Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.5±0.2°, 10.3±0.2°, 14.8±0.2°, 16.2±0.2°, 20.7±0.2°, and 21.6±0.2°.

[0015] In some embodiments, Compound 1 Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.5±0.2°, 10.3±0.2°, 14.8±0.2°, 15.4±0.2°, 16.2±0.2°, 19.8±0.2°, 20.7±0.2°, 21.6±0.2°, 22.8±0.2°, and 25.0±0.2°.

[0016] In some embodiments, compound 1 Form A has an XRPD pattern substantially as shown in FIG. 1A.

[0017] In some embodiments, Compound 1 Form A is characterized by having one endothermic peak at about 305° C. by differential scanning calorimetry (DSC).

[0018] In some embodiments, Compound 1 Form A has a DSC thermogram substantially as shown in FIG. 1D.

[0019] In some embodiments, Compound 1 Form A is anhydrous.

[0020] In a second aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide maleate, which is designated as Compound 1 maleate Form A.

[0021] In some embodiments, compound 1 maleate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 11.8±0.2°, 16.4±0.2°, and 21.8±0.2°.

[0022] In some embodiments, compound 1 maleate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 18.2±0.2°, 20.8±0.2°, and 21.8±0.2°.

[0023] In some embodiments, compound 1 maleate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 21.8±0.2°, and 23.9±0.2°.

[0024] In some embodiments, compound 1 maleate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 17.4±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 21.8±0.2°, and 23.9±0.2°.

[0025] In some embodiments, compound 1 maleate Form A has an XRPD pattern substantially as shown in FIG. 5A.

[0026] In some embodiments, Compound 1 maleate Form A is characterized by having one endothermic peak at about 215° C. by differential scanning calorimetry (DSC).

[0027] In some embodiments, compound 1 maleate Form A has a DSC thermogram substantially as shown in FIG. 5D.

[0028] In some embodiments, Compound 1 maleate Form A is anhydrous.

[0029] In a third aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamidophosphate, which is designated as Compound 1 Phosphate Form A.

[0030] In some embodiments, compound monophosphate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 11.1±0.2°, 12.6±0.2°, and 19.8±0.2°.

[0031] In some embodiments, compound monophosphate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, and 19.8±0.2°.

[0032] In some embodiments, compound monophosphate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, 18.1±0.2°, 19.8±0.2°, and 21.7±0.2°.

[0033] In some embodiments, Compound monophosphate Form A has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, 18.1±0.2°, 19.8±0.2°, 21.7±0.2°, 22.9±0.2°, and 24.1±0.2°.

[0034] In some embodiments, compound 1 phosphate Form A has an XRPD pattern substantially as shown in FIG. 4A.

[0035] In some embodiments, Compound 1 Phosphate Form A is characterized by having a single decomposition during the melting peak having an onset of 234° C. by differential scanning calorimetry (DSC).

[0036] In some embodiments, compound monophosphate Form A has a DSC thermogram substantially as shown in FIG. 4C.

[0037] In some embodiments, Compound 1 Phosphate Form A is anhydrous.

[0038] In a fourth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide hydrochloride, designated as Compound 1 Hydrochloride Form C.

[0039] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, and 21.3±0.2°.

[0040] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, and 21.3±0.2°.

[0041] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

[0042] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

[0043] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

[0044] In some embodiments, Compound 1 hydrochloride Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 16.2±0.2°, 18.1±0.2°, 19.2±0.2°, 19.9±0.2°, 21.3±0.2°, 24.0±0.2°, and 24.3±0.2°.

[0045] In some embodiments, the crystal system of Compound 1 Hydrochloride Form C is monoclinic and the space group is P21 / c with cell parameters: (a) is about 9.846(5), (b) is about 25.660(11) Å, (c) is about 10.975(4) Å, and (β) is about 92.551(15)°.

[0046] In some embodiments, Compound 1 hydrochloride Form C has an XRPD pattern substantially as shown in FIG. 2G.

[0047] In some embodiments, Compound 1 hydrochloride Form C has a DSC thermogram substantially as shown in FIG. 2I.

[0048] In a fifth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide hydrochloride, designated as Compound 1 hydrochloride Form D.

[0049] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.9±0.2° and 20.4±0.2°.

[0050] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, and 20.4±0.2°.

[0051] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 14.4±0.2°, 20.4±0.2°, and 23.5±0.2°.

[0052] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 14.4±0.2°, 17.5±0.2°, 20.4±0.2°, 21.6±0.2°, and 23.5±0.2°.

[0053] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern including diffraction peaks having degree 2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 13.2±0.2°, 14.4±0.2°, 17.5±0.2°, 19.1±0.2°, 20.4±0.2°, 21.6±0.2°, and 23.5±0.2°.

[0054] In some embodiments, Compound 1 hydrochloride Form D has an X-ray powder diffraction pattern including diffraction peaks having degree 2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 13.2±0.2°, 14.4±0.2°, 16.5±0.2°, 17.5±0.2°, 19.1±0.2°, 20.4±0.2°, 21.6±0.2°, 23.5±0.2°, and 24.9±0.2°.

[0055] In some embodiments, the crystal system of Compound 1 Hydrochloride Form D is monoclinic and the space group is P21 / n with cell parameters: (a) is about 10.309 Å, (b) is about 10.855(7) Å, (c) is about 24.995(17), and (β) is about 98.84(3)°.

[0056] In some embodiments, Compound 1 hydrochloride Form D has an XRPD pattern substantially as shown in FIG. 2K.

[0057] In some embodiments, Compound 1 hydrochloride Form D is characterized by having one endothermic peak at about 176° C. by differential scanning calorimetry (DSC).

[0058] In some embodiments, Compound 1 hydrochloride Form D has a DSC thermogram substantially as shown in Figure 2M.

[0059] In a sixth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide fumarate, designated as Compound 1 Fumarate Form B.

[0060] In some embodiments, Compound 1 fumarate Form B has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 12.2±0.2°, 15.5±0.2°, and 20.4±0.2°.

[0061] In some embodiments, compound 1 fumarate Form B has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, and 20.4±0.2°.

[0062] In some embodiments, compound 1 fumarate Form B has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, 19.6±0.2°, 20.4±0.2°, and 21.8±0.2°.

[0063] In some embodiments, compound 1 fumarate Form B has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, 19.6±0.2°, 20.4±0.2°, 21.8±0.2°, and 23.3±0.2°.

[0064] In some embodiments, the fumarate salt form B of compound 1 has an XRPD pattern substantially as shown in FIG. 6E.

[0065] In some embodiments, Compound 1 fumarate Form B is characterized by having one endothermic peak (melting peak) at about 235° C. by differential scanning calorimetry (DSC).

[0066] In some embodiments, compound 1 fumarate Form B has a DSC thermogram substantially as shown in FIG. 6G.

[0067] In some embodiments, Compound 1 fumarate Form B is anhydrous.

[0068] In a seventh aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide mesylate, designated as Compound 1 mesylate Form C.

[0069] In some embodiments, Compound 1 mesylate Form C has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, and 15.4±0.2°.

[0070] In some embodiments, Compound 1 mesylate Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, and 21.6±0.2°.

[0071] In some embodiments, Compound 1 mesylate Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 21.6±0.2°, and 23.0±0.2°.

[0072] In some embodiments, Compound 1 mesylate Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 21.6±0.2°, and 23.0±0.2°.

[0073] In some embodiments, Compound 1 mesylate Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.6±0.2°, 7.7±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 19.9±0.2°, 21.6±0.2°, and 23.0±0.2°.

[0074] In some embodiments, Compound 1 mesylate Form C has an XRPD pattern substantially as shown in FIG. 8I.

[0075] In some embodiments, Compound 1 mesylate Form C is characterized by having one endothermic peak at about 122° C. by differential scanning calorimetry (DSC).

[0076] In some embodiments, Compound 1 mesylate Form C has a DSC thermogram substantially as shown in Figure 8K.

[0077] In an eighth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, which is designated as Compound 1 Form E.

[0078] In some embodiments, Compound 1 Form E has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, and 18.4°±0.2°.

[0079] In some embodiments, Compound 1 Form E has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, and 18.4±0.2°.

[0080] In some embodiments, Compound 1 Form E has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, 18.4±0.2°, and 19.6°±0.2.

[0081] In some embodiments, Compound 1 Form E has an X-ray powder diffraction pattern including diffraction peaks having degree 2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, 16.5±0.2°, 18.4±0.2°, 19.6±0.2°, 21.7°±0.2, and 24.7±0.2°.

[0082] In some embodiments, compound 1 Form E has an XRPD pattern substantially as shown in Figure 10A.

[0083] In some embodiments, Compound 1 Form E is characterized by two endothermic peaks at about 81° C. and about 303° C., and one exothermic peak at about 148° C. by differential scanning calorimetry (DSC).

[0084] In some embodiments, Compound 1 Form E has a DSC thermogram substantially as shown in Figure 10B.

[0085] In a ninth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, designated as Compound 1 Form B.

[0086] In some embodiments, Compound 1 Form B has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 6.4±0.2°, 7.4°±0.2°, and 13.2±0.2°.

[0087] In some embodiments, Compound 1 Form B has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2°, 13.2±0.2°, and 17.7±0.2°.

[0088] In some embodiments, Compound 1 Form B has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2, 9.8°±0.2, 13.2±0.2°, and 17.7±0.2°.

[0089] In some embodiments, Compound 1 Form B has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2, 9.8°±0.2, 12.7±0.2°, 13.2±0.2°, 16.3±0.2°, 17.7±0.2°, and 18.1±0.2°.

[0090] In some embodiments, compound 1 Form B has an XRPD pattern substantially as shown in FIG. 1D.

[0091] In some embodiments, Compound 1 Form B is characterized by having four endothermic peaks at about 75° C., about 123° C., about 174° C., and about 301° C. by differential scanning calorimetry (DSC).

[0092] In some embodiments, Compound 1 Form B has a DSC thermogram substantially as shown in FIG. 1F.

[0093] In some embodiments, Compound 1 Form B is a heterosolvate of TFE and water.

[0094] In a tenth aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, designated as Compound 1 Form C.

[0095] In some embodiments, Compound 1 Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 14.8±0.2°, 17.7±0.2°, and 20.7°±0.2°.

[0096] In some embodiments, Compound 1 Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 14.8±0.2°, 17.4±0.2°, 17.7°±0.2, 20.7±0.2°, and 21.6±0.2°.

[0097] In some embodiments, Compound 1 Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 10.8±0.2°, 14.8±0.2°, 17.4°±0.2, 17.7±0.2°, 20.7±0.2°, and 21.6±0.2°.

[0098] In some embodiments, Compound 1 Form C has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 10.8±0.2°, 14.4±0.2°, 14.8°±0.2, 15.3±0.2°, 15.7±0.2°, 17.4±0.2°, 17.7±0.2°, 20.7±0.2°, and 21.6±0.2°.

[0099] In some embodiments, Compound 1 Form C has an XRPD pattern substantially as shown in Figure 1H.

[0100] In some embodiments, Compound 1 Form C is characterized by having an endothermic peak (Tonset) at about 86°C, followed by an endothermic peak at about 138°C, and a melting peak at about 303°C by differential scanning calorimetry (DSC).

[0101] In some embodiments, Compound 1 Form C has a DSC thermogram substantially as shown in Figure 1J.

[0102] In some embodiments, Compound 1 Form C is a 1,4-dioxane solvate.

[0103] In an eleventh aspect, disclosed herein is a crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, designated as Compound 1 Form D.

[0104] In some embodiments, Compound 1 Form D has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 16.1±0.2°, 16.5±0.2°, and 18.8°±0.2°.

[0105] In some embodiments, Compound 1 Form D has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 9.8±0.2°, 16.1±0.2°, 16.5°±0.2°, 18.1°±0.2°, and 18.8°±0.2°.

[0106] In some embodiments, Compound 1 Form D has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 9.4±0.2°, 9.8±0.2°, 16.1°±0.2°, 16.5°±0.2°, 18.1±0.2°, and 18.8±0.2°.

[0107] In some embodiments, Compound 1 Form D has an X-ray powder diffraction pattern comprising diffraction peaks having degree 2θ angle values ​​of 9.4±0.2°, 9.8±0.2°, 16.1°±0.2°, 16.5°±0.2°, 18.1±0.2°, 18.8±0.2°, 21.6±0.2°, 22.7±0.2°, and 24.2±0.2°.

[0108] In some embodiments, compound 1 Form D has an XRPD pattern substantially as shown in FIG. 1L.

[0109] In some embodiments, Compound 1 Form D is characterized by having an endothermic peak (Tonset) at about 105° C. followed by a melting peak at about 303° C. by differential scanning calorimetry (DSC).

[0110] In some embodiments, compound 1 Form D has a DSC thermogram substantially as shown in FIG. 1N.

[0111] In some embodiments, Compound 1 Form D is a chloroform solvate.

[0112] In some embodiments of all of the above aspects, the crystalline form has at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% crystallinity. In some embodiments of all of the above aspects, the crystalline form is at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% crystalline.

[0113] In a twelfth aspect, disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a crystalline form of Compound 1 or a crystalline form of a pharma- ceutically acceptable salt of Compound 1 as described in any one of the above aspects, and at least one pharma- ceutically acceptable excipient.

[0114] In a thirteenth aspect, disclosed herein is a method of treating an inflammatory or autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a crystalline form of Compound 1 or a crystalline form of a pharma- ceutically acceptable salt of Compound 1 as described in any one of the above aspects. In some embodiments, the subject is a human.

[0115] In some embodiments, disclosed herein is a process for preparing compound 1 Form A, the process comprising: a) dissolving Compound 1 in N-methylpyrrolidone or dimethylacetamide, adding acetone or butanone, and cooling to obtain Compound 1 Form A.

[0116] In some embodiments, disclosed herein is a process for preparing compound 1 Form A, the process comprising the steps of: a) dissolving Compound 1 in N-methylpyrrolidone, adding acetone and cooling to obtain Compound 1 Form A; or b) dissolving Compound 1 in dimethylacetamide, adding butanone and cooling to obtain Compound 1 Form A.

[0117] In some embodiments, disclosed herein is a process for preparing Compound 1 maleate Form A, the process comprising: a) adding Compound 1 or Compound 1 Form A and maleic acid to acetone, stirring, and cooling to obtain Compound 1 maleate Form A.

[0118] In some embodiments, disclosed herein is a process for preparing Compound monophosphate Form A, the process comprising: a) dissolving Compound 1 or Compound 1 Form A in ACN (acetonitrile) and adding phosphoric acid / ACN solution and stirring to obtain Compound 1 phosphate Form A.

[0119] In some embodiments, disclosed herein is a process for preparing Compound 1 hydrochloride Form C, the process comprising the steps of: a) dissolving Compound 1 or Compound 1 Form A in MeOH / HO (v / v=9 / 1), adding HCl, stirring and cooling to obtain Compound 1 hydrochloride Form C; b) dissolving Compound 1 or Compound 1 Form A in MeOH and adding HCl / MeOH solution, stirring and cooling to obtain Compound 1 hydrochloride Form C; c) dissolving Compound 1 or Compound 1 Form A in NMP / MeOH (v / v=1 / 4) and adding HCl / MeOH solution, stirring and cooling to obtain Compound 1 hydrochloride Form C; or d) dissolving Compound 1 or Compound 1 Form A in water, heating, adding HCl, stirring, adding acetone, and cooling to obtain Compound 1 hydrochloride Form C.

[0120] In some embodiments, disclosed herein is a process for preparing Compound 1 hydrochloride Form C, the process comprising the steps of: a) dissolving Compound 1 or Compound 1 Form A in MeOH / HO (v / v=9 / 1), adding HCl, stirring at less than about 50° C., and cooling to obtain Compound 1 hydrochloride Form C; b) dissolving Compound 1 or Compound 1 Form A in MeOH, heating to about 60° C., adding HCl / MeOH solution, stirring, and cooling to obtain Compound 1 hydrochloride Form C; c) dissolving Compound 1 or Compound 1 Form A in NMP / MeOH (v / v=1 / 4), adding HCl / MeOH solution, stirring below about 50° C., and cooling to obtain Compound 1 hydrochloride Form C; or d) dissolving Compound 1 or Compound 1 Form A in water, heating to about 50° C., adding HCl, stirring, adding acetone, and cooling to obtain Compound 1 hydrochloride Form C.

[0121] In some embodiments, disclosed herein is a process for preparing Compound 1 hydrochloride Form D, the process comprising: a) equilibrating Compound 1 hydrochloride Pattern A in a solvent / water system and ACN / water (90 / 10, v / v) to obtain Compound 1 hydrochloride Form D.

[0122] In some examples of these embodiments, the solvent / water system is acetone / water (90 / 10, v / v) and THF / water (85 / 15, v / v), or ACN / water (90 / 10, v / v) or acetone / water (80 / 20, v / v) and MEK / water (95 / 15, v / v), or ACN / water (90 / 10, v / v). More specifically, Compound 1 hydrochloride Form D can be obtained from acetone / water (90 / 10, v / v) and THF / water (85 / 15, v / v) by equilibration at 25° C. for 24 days, from ACN / water (90 / 10, v / v) by equilibration at 25° C. for 14 days, from acetone / water (80 / 20, v / v) and MEK / water (95 / 15, v / v) by equilibration at 25° C. for 76 days, and from ACN / water (90 / 10, v / v) by equilibration at 50° C. for 7 days.

[0123] In some embodiments, disclosed herein is a process for preparing Compound 1 hydrochloride Form D, the process comprising: a) equilibrating Compound 1 hydrochloride Pattern A in a solvent / water system at about 23° C. and ACN / water (90 / 10, v / v) at about 50° C. to obtain Compound 1 hydrochloride Form D.

[0124] In some examples of these embodiments, the solvent / water system is acetone / water (90 / 10, v / v) and THF / water (85 / 15, v / v), or ACN / water (90 / 10, v / v) or acetone / water (80 / 20, v / v) and MEK / water (95 / 15, v / v), or ACN / water (90 / 10, v / v). More specifically, Compound 1 hydrochloride Form D can be obtained from acetone / water (90 / 10, v / v) and THF / water (85 / 15, v / v) by equilibration at 25° C. for 24 days, from ACN / water (90 / 10, v / v) by equilibration at 25° C. for 14 days, from acetone / water (80 / 20, v / v) and MEK / water (95 / 15, v / v) by equilibration at 25° C. for 76 days, and from ACN / water (90 / 10, v / v) by equilibration at 50° C. for 7 days.

[0125] In some embodiments, disclosed herein is a process for preparing Compound 1 fumarate Form B, the process comprising the steps of: a) adding Compound 1 or Compound 1 Form A and fumaric acid to acetone and stirring to obtain Compound 1 fumarate salt Form B; or b) dissolving Compound 1 or Compound 1 Form A in ACN, adding fumaric acid and stirring to obtain Compound 1 fumarate Form B.

[0126] In some embodiments, disclosed herein is a process for preparing Compound 1 mesylate Form C, the process comprising: a) dissolving Compound 1 or Compound 1 Form A in acetone / HO (v / v=9 / 1), adding methanesulfonic acid and stirring to obtain Compound 1 mesylate Form C.

[0127] In some embodiments, any of the processes described above further comprise adding crystal seeds to the solution system. [Brief description of the drawings]

[0128] [Figure 1A]1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 Form A (anhydrous). [Figure 1B] 1 shows the differential scanning calorimetry (DSC) profile / thermogravimetric analysis (TGA) profile of Compound 1 Form A. [Figure 1C] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 Form A. [Figure 1D] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 Form B (heterosolvate of TFE and water). [Figure 1E] FIG. 1 shows the thermogravimetric analysis (TGA) profile of Compound 1 Form B (heterosolvate of TFE and water). [Figure 1F] 1 shows the differential scanning calorimetry (DSC) profile of Compound 1 Form B (heterosolvate of TFE and water). [Figure 1G] FIG. 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 Form B (heterosolvate of TFE and water). [Figure 1H] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 Form C (1,4-dioxane solvate). [Figure 1I] FIG. 1 shows the thermogravimetric analysis (TGA) profile of Compound 1 Form C (1,4-dioxane solvate). [Figure 1J] 1 shows the differential scanning calorimetry (DSC) profile of Compound 1 Form C (1,4-dioxane solvate). [Figure 1K] FIG. 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 Form C (1,4-dioxane solvate). [Figure 1L] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 Form D (chloroform solvate). [Figure 1M] FIG. 1 shows the thermogravimetric analysis (TGA) profile of Compound 1 Form D (chloroform solvate). [Figure 1N] 1 shows the differential scanning calorimetry (DSC) profile of Compound 1 Form D (chloroform solvate). [Figure 1O]1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of compound 1 form D (chloroform solvate). [Figure 2A] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 hydrochloride (1:1) Pattern A. [Figure 2B] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 hydrochloride pattern A. [Figure 2C] 1 shows the XRPD overlay patterns of Compound 1 hydrochloride (1:1) Form B. [Figure 2D] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 hydrochloride (1:1) Form B. [Figure 2E] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 hydrochloride (1:1) Form B. [Figure 2F] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 hydrochloride (1:1) form B. [Figure 2G] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 hydrochloride (1:1) Form C. [Figure 2H] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 hydrochloride (1:1) Form C. [Figure 2I] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 hydrochloride (1:1) Form C. [Figure 2J] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 hydrochloride (1:1) form C. [Figure 2K] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 hydrochloride (1:1) Form D. [Figure 2L] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 hydrochloride (1:1) Form D. [Figure 2M] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 hydrochloride (1:1) Form D. [Figure 2N] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 hydrochloride (1:1) form D. [Figure 2O]1 shows the calculated XRPD of the single crystal structure and the simulated XRPD of the single crystal of Compound 1 hydrochloride (1:1) Form C. [Figure 2P] 1 shows the calculated XRPD of the single crystal structure and the simulated XRPD of the single crystal of Compound 1 hydrochloride (1:1) Form D. [Figure 3A] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 sulfate Form A. [Figure 3B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 sulfate Form A. [Figure 3C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 sulfate Form A. [Figure 3D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 sulfate Form A. [Figure 3E] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 sulfate Form B. [Figure 3F] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 sulfate Form B. [Figure 3G] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 sulfate Form B. [Figure 3H] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 sulfate form B. [Figure 4A] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 phosphate Form A. [Figure 4B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 phosphate Form A. [Figure 4C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 phosphate Form A. [Figure 4D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 Phosphate Form A. [Figure 5A] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 maleate salt (1:1.0, anhydrous) Form A. [Figure 5B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 maleate salt (1:1.0, anhydrous) Form A. [Figure 5C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 maleate salt (1:1.0, anhydrous) Form A. [Figure 5D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 maleate salt (1:1.0, anhydrous) form A. [Figure 6A] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 fumarate Form A. [Figure 6B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 fumarate salt Form A. [Figure 6C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 fumarate salt Form A. [Figure 6D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 fumarate Form A. [Figure 6E] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 fumarate salt (1:0.5) form B. [Figure 6F] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 fumarate salt (1:0.5) form B. [Figure 6G] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 fumarate salt (1:0.5) Form B. [Figure 6H] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 fumarate salt (1:0.5) form B. [Figure 7A] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 HBr salt Form A (anhydrous). [Figure 7B] FIG. 1 shows the thermogravimetric analysis (TGA) profile of Compound 1 HBr salt Form A (anhydrous). [Figure 7C] FIG. 1 shows the differential scanning calorimetry (DSC) profile of Compound 1 HBr salt Form A (anhydrous). [Figure 7D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 HBr salt form A (anhydrous). [Figure 8A] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 mesylate Form A. [Figure 8B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 mesylate Form A. [Figure 8C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 mesylate Form A. [Figure 8D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 mesylate form A. [Figure 8E] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 mesylate Form B. [Figure 8F] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 mesylate Form B. [Figure 8G] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 mesylate Form B. [Figure 8H] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 mesylate form B. [Figure 8I] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 mesylate Form C. [Figure 8J] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 mesylate Form C. [Figure 8K] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 mesylate Form C. [Figure 8L] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 mesylate form C. [Figure 9A] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 esylate Form A. [Figure 9B] 1 shows a thermogravimetric analysis (TGA) profile of Compound 1 esylate Form A. [Figure 9C] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 esylate Form A. [Figure 9D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 esylate Form A. [Figure 9E] 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1 esylate Form B. [Figure 9F]1 shows a thermogravimetric analysis (TGA) profile of Compound 1 esylate Form B. [Figure 9G] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 esylate Form B. [Figure 9H] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of Compound 1 esylate Form B. [Figure 10A] 1 shows the X-ray powder diffraction (XRPD) pattern of Compound 1 Form E. [Figure 10B] 1 shows a differential scanning calorimetry (DSC) profile of Compound 1 Form E. [Figure 10C] 1 shows the thermogravimetric analysis (TGA) profile of Compound 1 Form E. [Figure 10D] 1 shows the 1H-nuclear magnetic resonance (1H-NMR) spectrum of compound 1 form E. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0129] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, patent applications, and publications mentioned herein are incorporated by reference.

[0130] As used herein, the term "solvate" refers to a crystalline form of Compound 1 that contains a solvent.

[0131] As used herein, the terms "subject," "individual," or "patient," used interchangeably, refer to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, primates, and humans. In some embodiments, the patient is a human. In some embodiments, the subject has experienced and / or exhibited at least one symptom of the disease or disorder being treated and / or prevented. In some embodiments, the subject is suspected of having a multi-tyrosine kinase-associated cancer.

[0132] As used herein, a "therapeutically effective amount" of a crystalline form of a salt of Compound 1 is an amount sufficient to ameliorate or in some manner reduce symptoms, or to halt or reverse the progression of a condition, or to negatively regulate or inhibit the activity of multiple tyrosine kinases. Such an amount may be administered as a single dose or according to a regimen, thereby being effective.

[0133] As used herein, treatment means any manner in which the symptoms or pathology of a condition, disorder, or disease are ameliorated or otherwise beneficially altered. Treatment also includes any pharmaceutical use of the compositions herein.

[0134] As used herein, alleviation of symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any alleviation, whether permanent or temporary, lasting or transient, that may result from or be associated with administration of the composition.

[0135] As used herein, the term "about" when used in reference to XRPD peak positions refers to the inherent variability of the peaks depending on the calibration of the instrument, the process used to prepare the crystalline forms of the present invention, the age of the crystalline form, and the type of instrument used for the analysis. The variability of the instrumentation used for the XRPD analysis was about 0.2 degrees 2θ.

[0136] As used herein, when used in reference to the DSC endothermic peak onset, the term "about" refers to the inherent variability of the peak depending on the calibration of the instrument, the method used to prepare the samples of the present invention, and the type of instrument used for the analysis. The variability of the instrumentation used for the DSC analysis was ±5°C, preferably ±2°C.

[0137] As used herein, the term "about" when used in reference to reaction conditions or procedures means that the variability in temperature was about ±5°C.

[0138] Common methods Unless otherwise stated, the general methods outlined below were used in the illustrated examples.

[0139] Crystallization Technology The crystalline forms disclosed herein may be prepared using a variety of methods well known to those skilled in the art, including by crystallization or recrystallization from a suitable solvent, or by sublimation. A wide variety of techniques may be used for crystallization or recrystallization, including evaporation of a water-miscible or water-immiscible solvent or solvent mixture, seeding with crystals in a supersaturated solution, lowering the temperature of a solvent mixture, or freeze-drying a solvent mixture, including those in the illustrated examples.

[0140] The crystallizations disclosed herein can be carried out with or without crystal seeds, which can come from any previous batch of the desired crystalline form.

[0141] Equipment and parameters For XRPD analysis, a Bruker D8 Advance (1D mode) with a LYNXEYE_XE_T as detector was used to characterize all physical forms obtained in this disclosure without any special indication. The XRPD parameters used are as follows: [Table 1]

[0142] TGA and DSC were used to characterize the physical forms obtained in this disclosure unless otherwise indicated; TGA data was collected using Discovery 5500 or Q5000 Instruments and DSC was performed using a TA Discovery 2500 Instrument.

[0143] Water content was tested using Karl Fischer (KF) and data was collected using a Mettler Toledo Coulometric KF Titrator C30 (method was coulometric) instrument.

[0144] The following examples are intended to illustrate further specific embodiments of the present invention and are not intended to limit the scope of the invention. EXAMPLES

[0145] Example 1A: Preparation of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide (Compound 1) [ka] Method A: Step 1: 1-(2,6-dibromopyridin-3-yloxy)-2-methylpropan-2-ol [ka] A 100 mL round bottom flask was charged with 2,6-dibromopyridin-3-ol (2.00 g, 7.90 mmol), DMF (30 mL), K2CO3 (3.28 g, 23.73 mmol), and 2,2-dimethyloxirane (0.68 g, 9.43 mmol). The resulting solution was stirred in an oil bath at 100 °C for 5 h. After cooling to room temperature, the resulting solution was diluted with H2O (50 mL), extracted with ethyl acetate (3 x 30 mL), and the organic layers were combined and concentrated. The residue was purified by CombiFlash (EtOAc / PE=1:4) to give the product (2.2 g, 85% yield). LCMS (ESI, m / z) [M+1] + 324.

[0146] Step 2: 6-Bromo-2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine [ka] A 100 mL round bottom flask was charged with 1-[(2,6-dibromopyridin-3-yl)oxy]-2-methylpropan-2-ol (2.00 g, 6.15 mmol), DMF (30 mL). To this, NaH (0.49 g, 60% in mineral oil, 12.30 mmol) was added in small portions at 0° C., and the resulting solution was stirred in an oil bath at 90° C. for 3 h. After cooling to room temperature, the reaction was quenched by adding aqueous NH4Cl (50 mL). The resulting solution was extracted with ethyl acetate (3×30 mL), and the organic layers were combined and concentrated. The residue was purified by CombiFlash (EtOAc / PE=1:6) to give the product (1.06 g, 71% yield).

[0147] 1 H NMR (400 MHz, CD3Cl) δ 7.06-7.02 (m, 2H), 4.08 (s, 2H), 1.38 (s, 6H).LCMS (ESI, m / z) [M+1] + 244, 246.

[0148] Step 3: 2-Chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-amine [ka] A solution of 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-amine (626.8 mg, 2.46 mmol), 6-bromo-2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (500 mg, 2.05 mmol), Pd(dppf)Cl2 (300 mg, 0.41 mmol), K3PO4 (869.2 mg, 4.1 mmol) in dioxane (8 mL) and H2O (2 mL) was stirred at 75 °C for 2 h. The mixture was cooled to room temperature and extracted between EA and H2O. The organic layer was concentrated. The crude product was purified by silica gel column chromatography (PE / EA=1:1) to give the desired product (440 mg, 73.57%). MS (ESI) m / e [M+1] + 292.

[0149] Step 4: N-(4-amino-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-2-yl)acetamide [ka] A solution of 2-chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-amine (440 mg, 1.51 mmol), acetamide (445.4 mg, 7.54 mmol), Pd2(dba)3 (276.6 mg, 0.3 mmol), Xant-phos (349.5 mg, 0.6 mmol), and Cs2CO3 (984.5 mg, 3 mmol) in dioxane (20 mL) was stirred at 130 °C for 5 h. The mixture was cooled to room temperature and filtered through Celite. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (DCM / MeOH=20:1) to give the desired product (305 mg, 64.26%). MS (ESI) m / e [M+1] + 315.

[0150] Step 5: N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide (compound 1) [ka] A solution of N-(4-amino-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-2-yl)acetamide (60 mg, 0.2 mmol), 2-bromo-6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridine (96 mg, 0.3 mmol), Pd2(dba)3 (36.6 mg, 0.04 mmol), Xantphos (46.3 mg, 0.08 mmol), and Cs2CO3 (130.4 mg, 0.4 mmol) in dioxane (3 mL) was stirred at 130° C. for 5 h. The mixture was cooled to room temperature and the solids were removed by filtration. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (DCM / MeOH=15 / 1) to give the product (63.6 mg, 57%). 1 H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 10.49 (s, 1H), 9.06 (s, 1H), 8.62 (s, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.52 - 7.38 (m, 2H), 7.05 (s, 1H), 4.26 (s, 2H), 4.01 - 3.92 (m, 2H), 3.49 - 3.44 (m, 2H), 3.43 (s, 3H), 3.02 - 2.89 (m, 1H), 2.11 (s, 3H), 1.84 - 1.74 (m, 2H), 1.72 - 1.59 (m, 2H), 1.37 (s, 6H).MS (ESI) m / e [M+1] + 554.

[0151] Method B: Step 1: Synthesis of 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-amine [ka] 5-Bromo-2-chloropyridin-4-amine (22.65 Kg), B2Pin2 (33.6 Kg), KOAc (21.4 Kg), and toluene (186.0 Kg) were charged into the reactor and the resulting mixture was exchanged with N2 three times, then palladium acetate (0.48 Kg) and butyldi-1-adamantylphosphine (0.14 Kg) were charged successively and the resulting mixture was stirred under N2 protection at 85-94 °C for 16-24 h. Upon completion of the reaction, the mixture was cooled to 25 °C, then EtOH (74.0 Kg) and water (120.0 Kg) were charged into the reactor and stirred at this temperature for 1 h. The organics were then separated and the mother liquor was extracted with EA (64.0 Kg x 2). The combined organic layers were filtered, then crystal seeds (1.65 kg) were charged and the mixture was stirred at this temperature for 0.5-2 h. The solid was collected by filtration and the filter cake was washed with MeOH (20.0 Kg) and dried at 40-50 °C for 24 h. The desired product was isolated in 77.9% yield.

[0152] Step 2: Synthesis of 2-chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-amine [ka] The reactor was charged with water (46.0 Kg), 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-amine (22.2 Kg), 6-bromo-2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (24.6 Kg), K3PO4 (36.8 kg), and isopropanol (140.0 kg), and the resulting mixture was exchanged with N2 three times. Palladium acetate (0.058 kg) and PCy3·HBF4 (0.190 kg) were then charged successively, and the resulting mixture was stirred at 60-70 °C for 16-24 h under N2 protection. Upon completion of the reaction, the reaction mixture was cooled to 40-50 °C, and the aqueous layer was separated. The organic layer was charged with crystal seeds (0.55 kg) and aged for 6-10 h. The solid was collected by filtration and the filter cake was washed with water (66.0 Kg) and dried at 40-50 °C for 15-25 h. The desired product was isolated in 85.2% yield.

[0153] Step 3: Synthesis of N-(2-chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-yl)-6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-amine [ka] A reactor was charged with 2-Me THF (184.0 Kg), 2-chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-amine (21.9 Kg), 2-chloro-6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridine (21.7 Kg), K3PO4 (31.5 kg), and water (20.0 Kg). The resulting mixture was exchanged with N2 three times and then charged with Pd2(dba)3 (0.73 kg) and Xantphos (0.90 kg). The mixture was stirred under N2 protection at 70-80 °C for 24-34 hours. Upon completion of the reaction, acetonitrile (44.0 Kg) was charged at 30-40° C. and the resulting mixture was stirred at this temperature for 4 hours. The solid was then collected by filtration and then dried at 45-55° C. for 15 hours. The desired product was isolated in 76% yield.

[0154] Step 4: Synthesis of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide [ka] A reactor was charged with 1,4-dioxane (230.0 kg), N-(2-chloro-5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-4-yl)-6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-amine (20.0 Kg), acetamide (3.5 Kg), and K3PO4 (16.0 Kg). The resulting mixture was exchanged with N2 three times, then allylpalladium(II) chloride dimer (0.152 kg) and dCypf (0.50 Kg) were added and the mixture was stirred at 95-105 °C for 12 h. After cooling to 20-30°C, acetic acid (4.1 Kg) and water (600.0 Kg) were charged and stirred at 20-30°C for 3 hours. The product was isolated by filtration. The crude product was washed with water (361.0 Kg) and dissolved in NMP (313 Kg) at 45-55°C. The filtrate was charged with water (320 Kg) and stirred at 20-30°C for 2 hours. The crude product was isolated by filtration and the filter cake was washed with water and dried at 45-55°C for 8-12 hours. The desired product was isolated in 56% yield.

[0155] Example 2A: Preparation of Compound 1 Form A Method A: Compound 1 (30 g) was added to N-methylpyrrolidone (NMP, 300 mL), and the resulting mixture was then heated to reflux to obtain a solution. Acetone (300 mL) was added to the solution, and the mixture was slowly cooled to room temperature (RT), stirred, and then the solid was collected by filtration, and the filter cake was washed with acetone and dried under reduced pressure to obtain the desired product (25.5 g).

[0156] The resulting product was characterized using X-ray powder diffraction (XRPD) pattern (performed with PANalytical X Pert3 XRPD on Si single crystal holder, K-Alpha1 [Å]: 1.54060 m, K-Alpha2 [Å]: 1.54443, 40 mA, 45 kV), which showed that the product was a crystalline form designated as Compound 1 Form A. See FIG. 1A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 1A. [Table 1A]

[0157] Compound 1 Form A 1 The H NMR spectrum was shown in Figure 1C. The DSC and TGA curves showed that a weight loss of 2.3% at 150 °C and one endothermic peak at 305 °C (peak) were observed (Figure 1B). The results indicated that Compound 1 Form A was anhydrous.

[0158] Method B: Compound 1 (30 g) was added to dimethylacetamide (DMAC, 300 mL) and the resulting mixture was heated to reflux to obtain a solution. Butanone (1000 mL) was then added to the solution, the mixture was slowly cooled to room temperature (RT) and stirred, and the solid was then collected by filtration, the filter cake was washed with butanone and dried under reduced pressure to obtain the desired product (22.5 g).

[0159] Example 2B: Preparation of Compound 1 Form B Compound 1 Form A (50-100 mg) was equilibrated in trifluoroethanol (TFE, 0.3-0.6 mL) at 50° C. for 1 week with stirring, then filtered by centrifugation to obtain the desired product.

[0160] The XRPD pattern was used to characterize the resulting product, which was shown to be crystalline and designated as Compound 1 Form B. See Figure 1D. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 1B. [Table 1B]

[0161] KF showed that Compound 1 Form B contained about 3.1% water by weight (1.0 equivalent molar ratio). 1 H-NMR showed about 7.1 wt% TFE (0.4 equiv. molar ratio, 0.4 equiv. molar ratio, FIG. 1G). TGA showed about 3.0% weight loss from 35°C to 80°C, about 3.3% weight loss from 80°C to 150°C, and about 3.0% weight loss from 150°C to 250°C (FIG. 1E). DSC showed multiple thermal events (FIG. 1F). The results indicated that Compound 1 Form B is a heterosolvate of TFE and water.

[0162] Example 2C: Preparation of Compound 1 Form C Compound 1 Form A (50-100 mg) was equilibrated in 0.3-0.7 mL of 1,4-dioxane at 25° C. for 2 weeks with stirring and then collected by centrifugation to give the desired product.

[0163] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 Form C. See Figure 1H. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 1C. [Table 1C]

[0164] The KF showed approximately 0.03 wt. % water (0.01 equivalent molar ratio). 1H-NMR showed about 9.5 wt% 1,4-dioxane (0.7 equivalent molar ratio) (FIG. 1K). TGA showed about 10.2% weight loss from 37°C to 120°C and about 4.2% weight loss from 120°C to 200°C (FIG. 1I). DSC showed an endothermic peak (Tonset) at 85.9°C, followed by an endothermic peak at 137.9°C, and a melting peak at 302.9°C (FIG. 1J), which suggested that Compound 1 Form C was converted to Compound 1 Form A after desolvation. The results indicated that Compound 1 Form C was a 1,4-dioxane solvate.

[0165] Example 2D: Preparation of Compound 1 Form D Compound 1 Form A (50-100 mg) was equilibrated in 0.3-0.7 mL of chloroform at 25° C. for 2 weeks with stirring and then collected by centrifugation to give the desired product.

[0166] The XRPD pattern was used to characterize the resulting product, which showed that it was in crystals, designated as Compound 1 Form D. See Figure 1L. The characteristic peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 1D. [Table 1D]

[0167] 1 H-NMR showed about 19.9% ​​chloroform by weight (1.2 equivalents molar ratio) (FIG. 1O). TGA showed about 20.4% weight loss at about 150° C. (FIG. 1M). DSC showed an endothermic peak (Tonset) at about 105° C., followed by a melting peak at about 303° C. (FIG. 1N). Compared with the DSC curve of Compound 1 Form A, Compound 1 Form D can be converted to Form A after desolvation. The results showed that Compound 1 Form D is a chloroform solvate.

[0168] Example 2E: Preparation of Compound 1 Form E 400mg of compound 1 hydrochloride form A (prepared by the method of Example 3A in this application) was weighed into a 20mL glass vial. 4mL of water was added to the vial under stirring at 37°C. 86mg of NaHCO3 (1.5 equivalents molar ratio) was dissolved in 2mL of water. The clear solution was then added to the suspension of hydrochloride form A for about 1 minute. After stirring for 30 minutes at 37°C, the solid was collected by suction filtration, washed with water three times, and then dried at ambient conditions for about 16 hours. Compound 1 form E was obtained as an off-white solid.

[0169] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 Form E. See Figure 10A. The characteristic peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 1E. [Table 1E]

[0170] Compound 1 Form E 1 The H NMR spectrum was shown in Figure 10D. The DSC and TGA curves showed that a weight loss of 4.3%-130°C and one endothermic peak at 303°C were observed (Figures 10C and 10B). The results indicated that Compound 1 Form E was a hydrate.

[0171] Example 2F: Physicochemical stability of Compound 1 Form A In the following experiments, which showed that Compound 1 Form A had good physicochemical stability, Compound 1 Form A still maintained the same form. Equilibration (25 °C) experiments carried out with 18 solvent systems selected from water, methanol, ethanol, acetone, ACN, ethyl acetate, THF, 2-MeTHF, DCM, DMSO, DMF, NMP, DMAc, MeOH / water (40:60, v / v), acetone / water (50:50, v / v), ACN / water (90:10, v / v), THF / water (85:15, v / v), and DMSO / water (30:70, v / v); Equilibration (50 °C) experiments carried out with 19 solvent systems selected from water, methanol, ethanol, acetone, ACN, ethyl acetate, 1,4-dioxane, THF, 2-MeTHF, CHCl3, DMSO, DMF, NMP, DMAc, MeOH / water (40:60, v / v), acetone / water (50:50, v / v), ACN / water (90:10, v / v), THF / water (85:15, v / v), and DMSO / water (30:70, v / v); • Slow evaporation experiments carried out in five solvent systems selected from DCM, CHCl3, DCM / MeOH (50:50, v / v), DCM / EtOH (50:50, v / v), and DCM / 2-MeTHF (50:50, v / v); • Fast evaporation experiments carried out in four solvent systems selected from DMSO, DMF, DCM, and DCM / MeOH (50:50, v / v); Antisolvent experiments carried out with eight solvent systems selected from DCM / heptane, DCM / MTBE, DMAc / water, DMAc / MTBE, NMP / water, NMP / MTBE, CHCl3 / heptane, and CHCl3 / MTBE; and ●DSC heating-cooling cycle experiment.

[0172] Example 3A: Preparation of Compound 1 Hydrochloride Form A Method A: To a mixture of compound 1 (10 g) in 300 mL of acetone / HO (v / v=9 / 1), about 1.0 equivalent of aqueous HCl (4N) was added under stirring at 50° C., and the resulting mixture was stirred at this temperature for 2 h, at 40° C. for 2 h, and then at room temperature for 16 h. The precipitated solid was collected by filtration, and the filter cake was washed with acetone and dried at 50° C. to obtain the product (9.0 g, yield: 84.5%).

[0173] X-ray powder diffraction (XRPD) pattern shows that the resulting product was a physical mixture of Compound 1 hydrochloride Forms C and D, which was highly crystalline and designated as Compound 1 hydrochloride Form A. See Figure 2A.

[0174] Method B: Compound 1 Form A (4 g) and Compound 1 hydrochloride Form A seeds (about 26 mg) were added to 120 mL of acetone / water (v / v=9 / 1) with stirring at 50° C. to obtain a slurry. HCl acetone / water solution (HCl (12N, 0.64 mL) in acetone / water (1.28 mL, v / v=9:1)) was slowly added to the mixture, followed by Compound 1 hydrochloride Form A seeds (24 mg), then stirred at 50° C. for about 2 hours, slowly cooled to 40° C., held at 40° C. for 2 hours, slowly cooled to room temperature, and held at room temperature for about 16 hours to obtain the desired product (4026 mg).

[0175] X-ray powder diffraction (XRPD) pattern indicates that the resulting product was a physical mixture of Compound 1 hydrochloride Form C and Form D, which was highly crystalline, designated as Compound 1 hydrochloride Pattern A. TGA showed a weight loss of about 0.9% at about 194° C. DSC showed no melting peak before decomposition. HPLC and ion chromatography (IC) showed Compound 1:HCl 1:1.0 with 1.4 wt % acetone residual, which was 1 1H-NMR (FIG. 2B). KF indicated that Compound 1 hydrochloride Form A contained about 0.3 wt. % water, corresponding to 0.1 water molecule.

[0176] Example 3B: Preparation of Compound 1 Hydrochloride Form B Compound 1 Form A (50 mg) and 1 equivalent of HCl were added to ACN (acetonitrile) and stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and the solid was collected by filtration to give the desired product.

[0177] The XRPD pattern was used to characterize the resulting product, which was shown to be in crystals designated as Compound 1 hydrochloride Form B. See Figure 2C. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 2A. [Table 2A]

[0178] 1 H-NMR showed about 1.2% ACN by weight (the stoichiometric ratio of compound 1:acid was 1:1.0, FIG. 2F). TGA showed about 3.7% weight loss from about 34 to 118 °C, and about 6.7% weight loss from about 118 to 228 °C (FIG. 2D). DSC showed a 37 °C endothermic peak (Tonset) at 66 °C, followed by a melting peak at 236 °C (FIG. 2E).

[0179] Example 3C: Preparation of Compound 1 Hydrochloride Form C Method A: To a mixture of compound 1 (10.0 g, 18.08 mmol) in 300 mL of MeOH / HO (v / v=9 / 1), about 1.0 equivalent of HCl (4N) was added under stirring at about 50° C., and the resulting mixture was stirred at about 50° C. for 16 h, then cooled slowly to room temperature. The precipitated solid was collected by filtration, and the filter cake was rinsed with MeOH (20 mL×2) and dried under vacuum at about 50° C. overnight to give 7.5 g of product (70.3% yield).

[0180] Method B: A mixture of compound 1 (10.0 g, 18.08 mmol) in 300 mL of MeOH (30v) was heated to about 60° C., then HCl / MeOH solution (3 M, 7.22 mL, 21.70 mmol, 1.2 equiv) was added dropwise, and the resulting mixture was stirred at about 60° C. for 16 h. After cooling to room temperature, the precipitated solid was collected by filtration, and the filter cake was rinsed with MeOH (20 mL×2) and dried under vacuum at 50° C. overnight to give 8.8 g of product (yield 82.3%).

[0181] Method C: To a mixture of compound 1 (1.0 g, 1.81 mmol) in 30 mL of NMP / MeOH (v / v=1 / 4), HCl / MeOH (3.0 M, 0.72 mL, 1.2 equiv.) solution was added dropwise under stirring at about 50° C., and the resulting mixture was stirred at this temperature for 16 h. After cooling to room temperature, the precipitated solid was collected by filtration, and the filter cake was rinsed with MeOH (20 mL×2) and dried under vacuum at 50° C. overnight to give 850 mg of product (yield 80.1%).

[0182] Method D: Compound 1 (11.92 kg) and water (6 volumes) were mixed. After heating to a temperature of about 50° C., 4N aqueous HCl (0.24 equiv.) was added, followed by crystal seeds of Compound 1 hydrochloride form C, and stirred for 1.5 hours to obtain a mixture. The mixture was added with 4N aqueous HCl in two batches (0.96 equiv., 0.3 equiv.) and then stirred for 9 hours and 2 hours, separately. Acetone (2 volumes) was added, stirred for 2 hours, then cooled to 10-20° C., and the solid was collected by filtration and dried to obtain the desired product (11.72 kg, HPLC purity 99.8%). 1H NMR (400 MHz, DMSO-d6) δ 12.04 (s, 1H), 11.53 (s, 1H), 8.67 (s, 1H), 8.58 (s, 1H), 7.61 (s, 1H), 7.53 (d, J = 6.0 Hz, 1H), 7.49 (d, J = 6.0 Hz, 1H), 7.20 (s, 1H), 4.26 (s, 2H), 3.95-3.97 (m, 2H), 3.44-3.42 (m, 5H), 3.03-2.97 (m, 1H), 2.20 (s, 3H), 1.81-1.80 (m, 2H), 1.75-1.61 (m, 2H), 1.36 (s, 6H).

[0183] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 hydrochloride Form C. See Figure 2G. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 2B. [Table 2B]

[0184] 1 H-NMR showed no solvent residues (Figure 2J). TGA showed no obvious weight loss from 30 to 150 °C (Figure 2H). DSC showed no thermal transition events from 30 to 200 °C, and began to dissociate at approximately 200 °C (Figure 2I). TGA data was collected using a Discovery 550 and DSC was performed using a TA Discovery 250 Instrument.

[0185] Example 3D: Preparation of Compound 1 Hydrochloride Form D Compound 1 hydrochloride Pattern A (500 mg) and ACN / water (90 / 10, v / v, 4.0 mL) were mixed and stirred at room temperature. After stirring at room temperature for about 20 days and at 50° C. for about 1 day, the solids in the stirred mixture were collected by filtration and then dried to obtain the desired product.

[0186] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 hydrochloride Form D. See Figure 2K. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 2C. [Table 2C]

[0187] 1 H-NMR showed about 0.07 wt% ACN (molar ratio 0.01 equivalents, Figure 2N). TGA showed about 0.6% weight loss from about 35 to 170 °C (Figure 2L). DSC showed an endothermic peak (Tonset) at 174 °C and 176 °C (Figure 2M).

[0188] Example 3E: Preparation of Compound 1 Hydrochloride Forms C and D in Single Crystals Compound 1 hydrochloride form C in single crystal Compound 1 hydrochloride form C (100 mg) and acetonitrile / water (90 / 10, v / v, 5 mL) were mixed. The resulting mixture was stirred at 50°C for 10 min, then stirred at 50°C for 10 min and filtered through a syringe membrane filter to obtain a clear solution. The solution was divided and transferred to vials and equilibrated under temperature cycling from 5°C to 50°C at a heating / cooling rate of 0.1°C / min for about 20 cycles. After temperature cycling, the sample was placed at ambient conditions (15-25°C, 50-80 RH) for about 9 days to obtain needle-like and plate crystals.

[0189] The plate crystals were then determined to be Compound 1 hydrochloride form D and the needle crystals were determined to be Compound 1 hydrochloride form C, which crystallized in the monoclinic system with the P21 / c space group. The crystallographic data were collected at 298 K on a single crystal X-ray diffractometer (SCXRD), Bruker D8 Venture equipped with a CMOS area detector (radiation was Mo / K-Alpha1 (λ=0.71073 Å), and the X-ray generator power was 50 kV, 1.4 mA). No solvent molecules were included. The simulated XRPD pattern (Figure 2O) based on the single crystal data at 298(2) K is in accordance with the XRPD of Compound 1 hydrochloride form C. [Table 2D]

[0190] Compound 1 hydrochloride form D in single crystal Compound 1 Form C (20 mg) and acetonitrile / water (80:20, v / v) were mixed. The resulting mixture was sonicated for about 30 seconds, heated at 50°C for about 10 minutes, and filtered through a syringe membrane filter to obtain a clear solution. The solution was allowed for slow evaporation of the solvent under ambient conditions (15-25°C, 50-80 RH) to obtain plate single crystals.

[0191] The crystal structure was determined by evaporation using the obtained plate crystals. The compound 1 hydrochloride crystals were crystallized in the monoclinic system with the P21 / n space group. The crystallographic data were collected at 298 K on a single crystal X-ray diffractometer (SCXRD), Bruker D8 Venture equipped with a CMOS area detector (radiation was Mo / K-Alpha1 (λ=0.71073 Å), X-ray generator power was 50 kV, 1.4 mA). No solvent molecules were included.

[0192] The simulated XRPD pattern (FIG. 2P) based on the 298 K single crystal data is in accordance with the XRPD of Compound 1 hydrochloride Form D. [Table 2E]

[0193] Example 4A: Preparation of Compound 1 Sulfate Form A Approximately 50 mg of Compound 1 Form A and 1 equivalent of H2SO4 (sulfuric acid) were added to acetone, stirred at 50°C for 2 hours, then at 25°C for at least 12 hours, and filtered to give the desired product.

[0194] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 sulfate Form A. See Figure 3A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 3A. [Table 3A]

[0195] 1 H-NMR showed about 0.2 wt% acetone (molar ratio 0.02 equivalents, stoichiometric ratio of compound 1:acid was 1:1.2, Figure 3D). TGA showed about 1.7% weight loss from about 34 to 129 °C (Figure 3B). DSC showed desolvation (Tonset) at 33 °C, followed by a melting peak at 226 °C (Figure 3C).

[0196] Example 4B: Preparation of Compound 1 Sulfate Form B Compound 1 Form A (50 mg) and 1 equivalent of H2SO4 were added to acetonitrile (ACN), stirred at 50°C for 2 hours, then at 25°C for at least 12 hours, and filtered to obtain Compound 1 sulfate Form B.

[0197] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 sulfate Form B. See Figure 3E. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 3B. [Table 3B]

[0198] 1 H-NMR showed about 0.8% ACN by weight (the stoichiometric ratio of compound 1:acid was 1:1.2, Figure 3H). TGA showed about 2.3% weight loss from about 34 to 125 °C (Figure 3F). DSC showed an endothermic peak (Tonset = 33 °C) at 45 °C, followed by a melting peak at 243 °C with an onset at 238 °C (Figure 3G).

[0199] Example 5A: Preparation of Compound 1 Phosphate Form A Method A: Compound 1 Form A (800 mg) was added to ACN (6.4 mL) and stirred at 50° C. to obtain a suspension. Phosphoric acid solution (0.2 mL of 85% aqueous solution, diluted with 1.8 mL of ACN, molar ratio of about 2.05 equivalents) was slowly added to the suspension, followed by Compound 1 phosphate Form A seeds (5 mg) and stirred at 50° C. for about 2 hours. Additional ACN (5 mL) was added to maintain the suspension and stirring was continued for about 1 day. The solid was collected by filtration and the filter cake was dried to obtain the desired product.

[0200] HPLC and IC showed that the stoichiometric ratio of compound 1:phosphate was approximately 1:2.2.

[0201] The XRPD pattern was used to characterize the resulting product and showed that it was in a crystalline form designated as Compound 1 phosphate Form A. See Figure 4A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 4A. [Table 4A]

[0202] 1 H-NMR showed 0.5 wt% ACN (0.10 equiv. molar ratio, Figure 4D). TGA showed a weight loss of about 0.9% from about 34 to about 180 °C (Figure 4B). DSC showed decomposition at a melting peak with an onset of 234 °C (Figure 4C). Karl Fischer showed 0.2 wt% water (0.08 equiv. molar ratio). The results indicated that Compound 1 Phosphate Form A is anhydrous.

[0203] Method B: Compound 1 Form A (50 mg) and 1 equivalent of H3PO4 (phosphoric acid) were added to acetone and stirred at 50°C for 2 hours, then at 25°C for at least 12 hours, and filtered to give the desired product.

[0204] Example 6A: Preparation of Compound 1 Maleate Salt Form A Compound 1 Form A (50 mg) and 1 equivalent of maleic acid were added to acetone, stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0205] The XRPD pattern was used to characterize the resulting product, which was shown to be in crystals and designated as Compound 1 maleate Form A. See Figure 5A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 5A. [Table 5A]

[0206] 1H-NMR showed no residual solvent (the stoichiometric ratio of compound 1:acid was 1:1.0, FIG. 5D). TGA showed a weight loss of about 0.4% from about 34 to 150 °C (FIG. 5B). DSC showed an endothermic peak with an onset of about 205 °C and a melting peak at about 215 °C (FIG. 5C). All the results indicated that compound 1 maleate form A is anhydrous.

[0207] Example 7A: Preparation of Compound 1 Fumarate Salt Form A Compound 1 Form A (50 mg) and 1 equivalent of fumaric acid were added to 2,2,2-trifluoroethanol (TFE), stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0208] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 fumarate Form A. See Figure 6A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 6A. [Table 6A]

[0209] 1 H-NMR showed no residual solvent (the stoichiometric ratio of compound 1:acid was 1:1.2, FIG. 6D). TGA showed a weight loss of about 2.2% from about 34 to 117 °C (FIG. 6B). DSC showed an endothermic peak at 51 °C (Tonset = 32 °C) followed by an onset of 221 °C and a melting peak at about 235 °C (FIG. 6C).

[0210] Example 7B: Preparation of Compound 1 Fumarate Salt Form B Method A: Compound 1 Form A (50 mg) and 1 equivalent of fumaric acid were added to acetone, stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0211] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 fumarate salt Form B. See Figure 6E. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 6B.

[0212] [Table 6B]

[0213] 1 H-NMR showed no residual solvent (the stoichiometric ratio of compound 1:acid was 1:0.5, FIG. 6H). TGA showed a weight loss of about 0.8% from about 34 to 129 °C (FIG. 6F). DSC showed no obvious melting peak (32 °C) followed by a melting peak with an onset of 221 °C and at about 235 °C (FIG. 6G). All the results indicated that compound 1 fumarate form B is anhydrous.

[0214] Method B: Compound 1 Form A (800 mg) and ACN (6.4 mL) were added under stirring at 50° C. to give a mixture.

[0215] The mixture was slowly added with fumaric acid (92.71 mg, molar ratio about 0.55 equivalents) and stirred for about 2 hours, then Compound 1 fumarate Form B seeds (5 mg) were added, cooled to room temperature, and stirred for about 1 day. The resulting solid was filtered and dried to give Compound 1 fumarate Form B (710 mg) as an off-white solid.

[0216] Compound 1 fumarate Form B was highly crystalline. DSC showed no melting peak before decomposition. TGA showed a weight loss of about 0.7% at about 150° C. 1 H-NMR showed that the ratio of compound 1:fumaric acid was 1:0.5, and no residual solvent was detected. KF shows that it contains about 0.3% water by weight, which corresponds to 0.1 water molecule.

[0217] Example 8A: Preparation of Compound 1 HBr Salt Form A Approximately 50 mg of Compound 1 Form A and 1 equivalent of HBr were added to acetone or ACN (acetonitrile), stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0218] The XRPD pattern was used to characterize the resulting product, which was shown to be in crystals and designated as Compound 1 HBr salt Form A. See Figure 7A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 7A. [Table 7A]

[0219] 1 H-NMR showed 0.6 wt% acetone (the stoichiometric ratio of compound 1:acid was 1:1.3, Figure 7D). TGA showed a weight loss of about 1.8% from about 33 to 129 °C (Figure 7B). DSC showed no obvious melting peak (Figure 7C). All the results indicated that compound 1 HBr salt form A is anhydrous.

[0220] Example 9A: Preparation of Compound 1 Mesylate Form A Compound 1 Form A (50 mg) and 1 equivalent of MSA (methanesulfonic acid) were added to acetone and stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0221] The XRPD pattern was used to characterize the resulting product, which was shown to be in crystals and designated as Compound 1 mesylate Form A. See Figure 8A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 8A. [Table 8A]

[0222] 1H-NMR showed 1.8 wt% acetone (molar ratio 0.20 equivalents, stoichiometric ratio of compound 1:acid was 1:1.1, FIG. 8D). TGA showed a weight loss of about 0.8% from about 34 to 70 °C (FIG. 8B). DSC showed an endothermic peak (Tonset=31.4) at 66 °C, followed by an exothermic peak with an onset of about 186 °C and a melting peak at about 194 °C (FIG. 8C), then an exothermic peak with an onset of about 200 °C.

[0223] Example 9B: Preparation of Compound 1 Mesylate Form B Approximately 50 mg of Compound 1 Form A and 1 equivalent of MSA were added to ACN (acetonitrile), stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to give the desired product.

[0224] The XRPD pattern was used to characterize the resulting product, which showed that it was in crystals, designated as Compound 1 mesylate Form B. See Figure 8E. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 8B. [Table 8B]

[0225] 1 H-NMR showed 0.6 wt% ACN (molar ratio 0.09 equivalents, stoichiometric ratio of compound 1:acid was 1:1.1, Figure 8H). TGA showed a weight loss of about 2.7% from about 31 to 124 °C (Figure 8F). DSC showed an endothermic peak at 66 °C (Tonset = 57 °C) followed by an exothermic peak with an onset of 215 °C (Figure 8G).

[0226] Example 9C: Preparation of Compound 1 Mesylate Form C To a mixture of compound 1 (20 g, 7.2 mmol) in 400 mL of acetone / HO (v / v=9 / 1), about 1.0 equivalent of methanesulfonic acid (MSA) (3.47 g, 7.2 mmol) was added under stirring at 20° C., and the solution was stirred at 20° C. for 5 h and filtered. The filter cake was washed with acetone and dried at 50° C. to give the desired product (18 g).

[0227] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 mesylate Form C. See Figure 8I. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 8C. [Table 8C]

[0228] 1 H-NMR showed 0.4 wt% acetone (stoichiometric ratio of compound 1:acid was 1:1.1, FIG. 8L). TGA showed about 1.9% weight loss at about 80°C, and about 4.4% weight loss from 80°C to 130°C (FIG. 8J). DSC showed an endothermic peak at about 122°C (Tonset=57°C) followed by an exothermic peak (FIG. 8K). KF showed it contained about 6.3 wt% water, molar ratio 2.4 equivalents.

[0229] Example 10A: Preparation of Compound 1 Esylate Form A Compound 1 Form A (50 mg) and 1 equivalent of ethanesulfonic acid were added to acetone, stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to obtain Compound 1 esylate Form A.

[0230] The XRPD pattern was used to characterize the resulting product, which was shown to be in crystals and designated as Compound 1 esylate Form A. See Figure 9A. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 9A. [Table 9A]

[0231] 1H-NMR showed 0.2 wt% acetone (molar ratio 0.03 equivalents, stoichiometric ratio of compound 1:acid was 1:1.1, FIG. 9D). TGA showed a weight loss of about 1.4% from about 35°C to 230°C (FIG. 9B). DSC showed an endothermic peak at about 257°C (Tonset=257°C) (FIG. 9C).

[0232] Example 10B: Preparation of Compound 1 Esylate Form B Approximately 50 mg of Compound 1 Form A and 1 equivalent of ethanesulfonic acid were added to ACN (acetonitrile), stirred at 50° C. for 2 hours, then at 25° C. for at least 12 hours, and filtered to obtain.

[0233] The XRPD pattern was used to characterize the resulting product and showed that it was in crystals, designated as Compound 1 esylate Form B. See Figure 9E. The peaks and peak intensity percentages obtained from the XRPD analysis are listed in Table 9B. [Table 9B]

[0234] 1 H-NMR showed 0.4 wt% ACN (molar ratio 0.07 equivalents, stoichiometric ratio of compound 1:acid was 1:1.0, FIG. 9H). TGA showed about 2.6% weight loss from 34°C to 100°C, and 0.7% weight loss from 100°C to 161°C (FIG. 9F). DSC showed an endothermic peak at 87°C (Tonset=34°C) followed by a melting peak at 133°C onset and 141°C, and an exothermic peak with an onset of 178.9°C (FIG. 9G).

[0235] Example 11: Evaluation of Different Forms of Compound 1 Salt 1) Bulk stability The bulk stability of Compound 1 mesylate Form C, phosphate Form A, maleate Form A, and fumarate Form B was investigated at 25° C. / 60% RH in open containers and at 40° C. / 75% RH in open containers for one week. The bulk stability of Compound 1 hydrochloride Forms C and D was evaluated at 25° C. / 60% RH in open containers, at 40° C. / 75% RH in open containers, and at 60° C. in closed containers for one week. All physical forms were physically and chemically stable under these conditions.

[0236] In addition, some forms were physically and chemically stable in closed containers at 25° C. / 60% RH, 30° C. / 65% RH, and 40° C. / 75% RH for over six months.

[0237] 2) Solubility The solubilities of Compound 1 mesylate Form C, phosphate Form A, maleate Form A, and fumarate Form B were measured in six aqueous pH buffers and biorelevant solutions including pH 1.2 HCl solution (0.1N), pH 4.5 acetate buffer (50 mM), water, pH 2.0 SGF, pH 6.5 FaSSIF-v1, and pH 5.0 FeSSIF-v1 for 1 and 2 hours at 37° C. The residual solids after the solubility studies were analyzed by XRPD.

[0238] All four salts showed pH-dependent solubility profiles. The four salts showed relatively high solubility (0.1-0.7 mg / mL in free form) in pH 1.2 buffer, which decreased to about 0.001 mg / mL in pH 4.5 buffer. In SGF, phosphate form A showed the highest solubility of about 0.74 mg / mL at 1 h. In FeSSIF-v1 and FaSSIF-v1, all four salts showed similar solubility in pH 4.5 buffer. After the solubility test, the residual solids were converted to latent hydrochloride salts in pH 1.2 buffer and SGF medium, or to free forms in other media except fumarate, which remained unchanged in SGF.

[0239] 3) Hygroscopicity The hygroscopicity of Compound 1 mesylate Form C, phosphate Form A, maleate Form A, fumarate Form B, hydrochloride Form C, and hydrochloride Form D was evaluated by dynamic vapor sorption (DVS) testing at 25°C. Compound 1 mesylate form C is slightly hygroscopic. It absorbed about 1.1% water from 40% RH to 95% RH at 25°C. There was no change in morphology and crystallinity after DVS testing. Compound 1 phosphate form A is slightly hygroscopic. It absorbed about 2.3% water from 40% RH to 95% RH at 25°C. There was no change in morphology and crystallinity after DVS test. Compound 1 maleate form A is slightly hygroscopic. It absorbed about 0.4% water from 40% RH to 95% RH at 25°C. There was no change in morphology and crystallinity after DVS testing. ● Compound 1 fumarate form B was stable at 0% RH to 40% RH. However, it started to absorb water and converted to latent hydrate when the relative humidity exceeded 40%. The latent hydrate went through dehydration and reverted to anhydrous form when RH<70%. After DVS test, the obtained sample was still Compound 1 fumarate form B. Compound 1 hydrochloride form C is slightly hygroscopic. It absorbed about 0.29% water from 40% RH to 95% RH at 25°C. There was no change in the morphology after DVS testing. Compound 1 hydrochloride form D is non-hygroscopic. It absorbed about 0.14% water from 40% RH to 95% RH at 25°C. After DVS test. There was no change in the form after DVS test.

[0240] 4) Feasibility of the blending process The feasibility of compounding processes for Compound 1 mesylate Form C, phosphate Form A, maleate Form A, fumarate Form B, hydrochloride Form C, and hydrochloride Form D was evaluated by compression (2 MPa, 5 MPa, 10 MPa, and 20 MPa), dry milling, and granulation simulation experiments.

[0241] All salts showed good resistance to compression, dry grinding, and granulation simulation, with no morphological change and obvious crystallinity loss, except for Compound 1 fumarate Form B. After dry grinding and compression, Compound 1 fumarate Form B showed morphological change. However, the peaks of Compound 1 hydrochloride Form D became slightly broader after compression under 5 MPa and 10 MPa.

[0242] Compound 1 hydrochloride Form C exhibited good resistance to compression without morphological changes or obvious loss of crystallinity, although the peaks were slightly broadened when compressed at 5 MPa, 10 MPa, and 20 MPa.

[0243] While the invention has been described in relation to specific embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover generally any variations, uses, or adaptations of the invention in accordance with the principles of the invention, including such departures from the present disclosure as are within known or customary practice in the art to which this invention pertains and as may be applicable to the essential features set forth hereinbefore, and within the scope of the appended claims.

Claims

1. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide or a pharma- ceutically acceptable salt thereof.

2. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, said form being designated as Compound 1 Form A.

3. 3. The crystalline form of claim 2, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 10.3±0.2°, 14.8±0.2°, and 16.2°±0.2°.

4. 3. The crystalline form of claim 2, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 10.3±0.2°, 14.8±0.2°, 16.2±0.2°, 20.7±0.2°, and 21.6±0.2°.

5. 3. The crystalline form of claim 2, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.5±0.2°, 10.3±0.2°, 14.8±0.2°, 16.2±0.2°, 20.7±0.2°, and 21.6±0.2°.

6. 3. The crystalline form of claim 2, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.5±0.2°, 10.3±0.2°, 14.8±0.2°, 15.4±0.2°, 16.2±0.2°, 19.8±0.2°, 20.7±0.2°, 21.6±0.2°, 22.8±0.2°, and 25.0±0.2°.

7. The crystalline form of any one of claims 2 to 6, wherein Compound 1 Form A has an XRPD pattern substantially as shown in Figure 1A.

8. The crystalline form of any one of claims 2 to 7, wherein Compound 1 Form A is characterized by having one endothermic peak at about 305°C by Differential Scanning Calorimetry (DSC).

9. 8. The crystalline form of any one of claims 2-7, wherein Compound 1 Form A has a DSC thermogram substantially as shown in Figure 1B.

10. 1. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide maleate, said form being designated as Compound 1 maleate Form A.

11. 11. The crystalline form of claim 10, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 11.8±0.2°, 16.4±0.2°, and 21.8±0.2°.

12. 11. The crystalline form of claim 10, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 18.2±0.2°, 20.8±0.2°, and 21.8±0.2°.

13. 11. The crystalline form of claim 10, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 21.8±0.2°, and 23.9±0.2°.

14. 11. The crystalline form of claim 10, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 5.6±0.2°, 11.8±0.2°, 16.4±0.2°, 17.4±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 21.8±0.2°, and 23.9±0.2°.

15. The crystalline form of any one of claims 10-14, wherein Compound 1 maleate Form A has an XRPD pattern substantially as shown in Figure 5A.

16. The crystalline form of any one of claims 10 to 15, wherein Compound 1 maleate Form A is characterized by having one endothermic peak at about 215°C by differential scanning calorimetry (DSC).

17. 16. The crystalline form of any one of claims 10-15, wherein Compound 1 maleate Form A has a DSC thermogram substantially as shown in Figure 5C.

18. 1. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamidophosphate, said form being designated as Compound 1 phosphate Form A.

19. 20. The crystalline form of claim 18, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 11.1±0.2°, 12.6±0.2°, and 19.8±0.2°.

20. 20. The crystalline form of claim 18, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, and 19.8±0.2°.

21. 20. The crystalline form of claim 18, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, 18.1±0.2°, 19.8±0.2°, and 21.7±0.2°.

22. 20. The crystalline form of claim 18, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.0±0.2°, 11.1±0.2°, 12.6±0.2°, 14.5±0.2°, 18.1±0.2°, 19.8±0.2°, 21.7±0.2°, 22.9±0.2°, and 24.1±0.2°.

23. 23. The crystalline form of any one of claims 18-22, wherein compound 1 phosphate Form A has an XRPD pattern substantially as shown in Figure 4A.

24. 23. The crystalline form of any one of claims 18 to 22, wherein compound 1 phosphate Form A is characterized by having a single decomposition during the melting peak having an onset of 234°C by Differential Scanning Calorimetry (DSC).

25. 23. The crystalline form of any one of claims 18-22, wherein compound 1 phosphate Form A has a DSC thermogram substantially as shown in Figure 4C.

26. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide hydrochloride, said form being designated as Compound 1 hydrochloride Form C.

27. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, and 21.3±0.2°.

28. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, and 21.3±0.2°.

29. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

30. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

31. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 18.1±0.2°, 19.9±0.2°, 21.3±0.2°, and 24.0±0.2°.

32. 27. The crystalline form of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 9.1±0.2°, 13.8±0.2°, 16.2±0.2°, 18.1±0.2°, 19.2±0.2°, 19.9±0.2°, 21.3±0.2°, 24.0±0.2°, and 24.3±0.2°.

33. The crystal system of Compound 1 hydrochloride Form C is monoclinic and has a space group P2 with cell parameters: (a) is about 9.846(5), (b) is about 25.660(11) Å, (c) is about 10.975(4) Å, and (β) is about 92.551(15)°. 1 The crystalline form of any one of claims 26 to 32, wherein:

34. The crystalline form of any one of claims 26-33, wherein Compound 1 hydrochloride Form C has an XRPD pattern substantially as shown in Figure 2G.

35. The crystalline form of any one of claims 26-34, wherein Compound 1 hydrochloride Form C has a DSC thermogram substantially as shown in Figure 2I.

36. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide hydrochloride, said form being designated as Compound 1 hydrochloride Form D.

37. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.9±0.2° and 20.4±0.2°.

38. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, and 20.4±0.2°.

39. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 14.4±0.2°, 20.4±0.2°, and 23.5±0.2°.

40. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 14.4±0.2°, 17.5±0.2°, 20.4±0.2°, 21.6±0.2°, and 23.5±0.2°.

41. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 13.2±0.2°, 14.4±0.2°, 17.5±0.2°, 19.1±0.2°, 20.4±0.2°, 21.6±0.2°, and 23.5±0.2°.

42. 37. The crystalline form of claim 36, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 7.2±0.2°, 9.9±0.2°, 13.2±0.2°, 14.4±0.2°, 16.5±0.2°, 17.5±0.2°, 19.1±0.2°, 20.4±0.2°, 21.6±0.2°, 23.5±0.2°, and 24.9±0.2°.

43. The crystal system of Compound 1 hydrochloride Form D is monoclinic and the space group is P2 with cell parameters: (a) is about 10.309 Å, (b) is about 10.855(7) Å, (c) is about 24.995(17), and (β) is about 98.84(3)°. 1 / n.

44. The crystalline form of any one of claims 35-43, wherein Compound 1 hydrochloride Form D has an XRPD pattern substantially as shown in Figure 2K.

45. 45. The crystalline form of any one of claims 36 to 44, wherein Compound 1 hydrochloride Form D is characterized by having one endothermic peak at about 176°C by Differential Scanning Calorimetry (DSC).

46. The crystalline form of any one of claims 36-44, wherein Compound 1 hydrochloride Form D has a DSC thermogram substantially as shown in Figure 2M.

47. 1. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide fumarate, said form being designated as Compound 1 fumarate Form B.

48. 48. The crystalline form of claim 47, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 12.2±0.2°, 15.5±0.2°, and 20.4±0.2°.

49. 48. The crystalline form of claim 47, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, and 20.4±0.2°.

50. 48. The crystalline form of claim 47, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, 19.6±0.2°, 20.4±0.2°, and 21.8±0.2°.

51. 48. The crystalline form of claim 47, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.9±0.2°, 12.2±0.2°, 15.5±0.2°, 17.2±0.2°, 19.6±0.2°, 20.4±0.2°, 21.8±0.2°, and 23.3±0.2°.

52. 52. The crystalline form of any one of claims 47-51, wherein Compound 1 fumarate Form B has an XRPD pattern substantially as shown in Figure 6E.

53. 53. The crystalline form of any one of claims 47 to 52, wherein Compound 1 fumarate Form B is characterized by having one endothermic peak (melting peak) at about 235°C by differential scanning calorimetry (DSC).

54. 53. The crystalline form of any one of claims 47-52, wherein Compound 1 fumarate Form B has a DSC thermogram substantially as shown in Figure 6G.

55. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide mesylate, said form being designated as Compound 1 mesylate Form C.

56. 56. The crystalline form of claim 55, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, and 15.4±0.2°.

57. 56. The crystalline form of claim 55, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, and 21.6±0.2°.

58. 56. The crystalline form of claim 55, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 21.6±0.2°, and 23.0±0.2°.

59. 56. The crystalline form of claim 55, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 21.6±0.2°, and 23.0±0.2°.

60. 56. The crystalline form of claim 55, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.6±0.2°, 7.7±0.2°, 13.3±0.2°, 15.4±0.2°, 16.6±0.2°, 19.9±0.2°, 21.6±0.2°, and 23.0±0.2°.

61. The crystalline form of any one of claims 55-60, wherein Compound 1 mesylate Form C has an XRPD pattern substantially as shown in Figure 8I.

62. 62. The crystalline form of any one of claims 55-61, wherein Compound 1 mesylate Form C is characterized by having one endothermic peak at about 122°C by differential scanning calorimetry (DSC).

63. 62. The crystalline form of any one of claims 55-61, wherein Compound 1 mesylate Form C has a DSC thermogram substantially as shown in Figure 8K.

64. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, said form being designated as Compound 1 Form E.

65. 65. The crystalline form of claim 64, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, and 18.4°±0.2°.

66. 65. The crystalline form of claim 64, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, and 18.4±0.2°.

67. 65. The crystalline form of claim 64, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, 18.4±0.2°, and 19.6°±0.

2.

68. 65. The crystalline form of claim 64, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.3±0.2°, 6.9±0.2°, 13.1°±0.2, 13.7°±0.2, 16.5±0.2°, 18.4±0.2°, 19.6±0.2°, 21.7°±0.2, and 24.7°±0.

2.

69. 69. The crystalline form of any one of claims 64-68, wherein Compound 1 Form E has an XRPD pattern substantially as shown in Figure 10A.

70. 70. The crystalline form of any one of claims 64-69, wherein Compound 1 Form E is characterized by having two endothermic peaks at about 81°C and about 303°C and one exothermic peak at about 148°C by Differential Scanning Calorimetry (DSC).

71. 70. The crystalline form of any one of claims 64-69, wherein Compound 1 Form E has a DSC thermogram substantially as shown in Figure 10B.

72. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, said form being designated as Compound 1 Form B.

73. 73. The crystalline form of claim 72, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 6.4±0.2°, 7.4°±0.2°, and 13.2±0.2°.

74. 73. The crystalline form of claim 72, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2°, 13.2±0.2°, and 17.7±0.2°.

75. 73. The crystalline form of claim 72, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2, 9.8°±0.2, 13.2±0.2°, and 17.7±0.2°.

76. 73. The crystalline form of claim 72, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 4.9±0.2°, 6.4±0.2°, 7.4°±0.2, 9.8°±0.2, 12.7±0.2°, 13.2±0.2°, 16.3±0.2°, 17.7±0.2°, and 18.1±0.2°.

77. 77. The crystalline form of any one of claims 72-76, wherein Compound 1 Form B has an XRPD pattern substantially as shown in Figure ID.

78. 78. The crystalline form of any one of claims 72-77, wherein Compound 1 Form B is characterized by having four endothermic peaks at about 75°C, about 123°C, about 174°C, and about 301°C by Differential Scanning Calorimetry (DSC).

79. 78. The crystalline form of any one of claims 72-77, wherein Compound 1 Form B has a DSC thermogram substantially as shown in Figure 1F.

80. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, said form being designated as Compound 1 Form C.

81. 81. The crystalline form of claim 80, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 14.8±0.2°, 17.7±0.2°, and 20.7°±0.2°.

82. 81. The crystalline form of claim 80, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 14.8±0.2°, 17.4±0.2°, 17.7°±0.2, 20.7±0.2°, and 21.6±0.2°.

83. 81. The crystalline form of claim 80, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 10.8±0.2°, 14.8±0.2°, 17.4°±0.2, 17.7±0.2°, 20.7±0.2°, and 21.6±0.2°.

84. 81. The crystalline form of claim 80, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 10.8±0.2°, 14.4±0.2°, 14.8°±0.2, 15.3±0.2°, 15.7±0.2°, 17.4±0.2°, 17.7±0.2°, 20.7±0.2°, and 21.6±0.2°.

85. 85. The crystalline form of any one of claims 80-84, wherein Compound 1 Form C has an XRPD pattern substantially as shown in Figure 1H.

86. 86. The crystalline form of any one of claims 80-85, wherein Compound 1 Form C is characterized by having an endothermic peak (Tonset) at about 86°C, followed by an endothermic peak at about 138°C, and a melting peak at about 303°C by Differential Scanning Calorimetry (DSC).

87. 86. The crystalline form of any one of claims 80-85, wherein Compound 1 Form C has a DSC thermogram substantially as shown in Figure 1J.

88. A crystalline form of N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide, said form being designated as Compound 1 Form D.

89. 90. The crystalline form of claim 88, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 16.1±0.2°, 16.5±0.2°, and 18.8°±0.2°.

90. 90. The crystalline form of claim 88, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.8±0.2°, 16.1±0.2°, 16.5°±0.2°, 18.1°±0.2°, and 18.8°±0.2°.

91. 90. The crystalline form of claim 88, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.4±0.2°, 9.8±0.2°, 16.1°±0.2°, 16.5°±0.2°, 18.1±0.2°, and 18.8±0.2°.

92. 89. The crystalline form of claim 88, wherein the crystalline form has an X-ray powder diffraction pattern comprising diffraction peaks having °2θ angle values ​​of 9.4±0.2°, 9.8±0.2°, 16.1°±0.2°, 16.5°±0.2°, 18.1±0.2°, 18.8±0.2°, 21.6±0.2°, 22.7±0.2°, and 24.2±0.2°.

93. 93. The crystalline form of any one of claims 88-92, wherein Compound 1 Form D has an XRPD pattern substantially as shown in Figure 1L.

94. 94. The crystalline form of any one of claims 88-93, wherein Compound 1 Form D is characterized by having an endothermic peak (T onset) at about 105°C followed by a melting peak at about 303°C by Differential Scanning Calorimetry (DSC).

95. 94. The crystalline form of any one of claims 88-93, wherein Compound 1 Form D has a DSC thermogram substantially as shown in Figure 1N.

96. 96. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of any one of claims 1 to 95 and at least one pharma- ceutically acceptable excipient.

97. 100. A method for treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a crystalline form of any one of claims 1-95.

98. 98. The method of claim 97, wherein the subject is a human.

99. A process for preparing the crystalline form of any one of claims 2 to 9, comprising the steps of: a) dissolving compound 1 in N-methylpyrrolidone or dimethylacetamide, adding acetone or butanone, and cooling to obtain compound 1 form A.

100. A process for preparing the crystalline form of any one of claims 2 to 9, comprising the steps of: a) dissolving Compound 1 in N-methylpyrrolidone, adding acetone and cooling to obtain Compound 1 Form A; or b) dissolving Compound 1 in dimethylacetamide, adding butanone and cooling to obtain Compound 1 Form A.

101. A process for preparing the crystalline form of any one of claims 10 to 17, comprising the steps of: a) adding Compound 1 or Compound 1 Form A and maleic acid to acetone, stirring and cooling to obtain Compound 1 maleate Form A.

102. A process for preparing the crystalline form of any one of claims 18 to 25, comprising the steps of: a) dissolving Compound 1 or Compound 1 Form A in ACN (acetonitrile) and adding phosphoric acid / ACN solution and stirring to obtain Compound 1 phosphate Form A.

103. A process for preparing the crystalline form of any one of claims 26 to 35, comprising the steps of: a) Compound 1 or Compound 1 Form A was dissolved in MeOH / H 2 2. Dissolving in 2,4-dichlorophenyl ether (v / v=9 / 1), adding HCl, stirring and cooling to obtain Compound 1 hydrochloride Form C; b) dissolving Compound 1 or Compound 1 Form A in MeOH and adding HCl / MeOH solution, stirring and cooling to obtain Compound 1 hydrochloride Form C; c) dissolving Compound 1 or Compound 1 Form A in NMP / MeOH (v / v=1 / 4) and adding HCl / MeOH solution, stirring and cooling to obtain Compound 1 hydrochloride Form C; or d) dissolving Compound 1 or Compound 1 Form A in water, heating, adding HCl, stirring, adding acetone, and cooling to obtain Compound 1 hydrochloride Form C.

104. A process for preparing the crystalline form of any one of claims 26 to 35, comprising the steps of: a) Compound 1 or Compound 1 Form A was dissolved in MeOH / H 2 2. Dissolving in 2,4-dichlorophenyl ether (v / v=9 / 1), adding HCl, stirring at less than about 50° C., and cooling to obtain Compound 1 hydrochloride Form C; b) dissolving Compound 1 or Compound 1 Form A in MeOH, heating to about 60° C., adding HCl / MeOH solution, stirring, and cooling to obtain Compound 1 hydrochloride Form C; c) dissolving Compound 1 or Compound 1 Form A in NMP / MeOH (v / v=1 / 4), adding HCl / MeOH solution, stirring below about 50° C., and cooling to obtain Compound 1 hydrochloride Form C; or d) dissolving Compound 1 or Compound 1 Form A in water, heating to about 50° C., adding HCl, stirring, adding acetone, and cooling to obtain Compound 1 hydrochloride Form C.

105. A process for preparing the crystalline form of any one of claims 36 to 46, comprising the steps of: a) dissolving Compound 1 hydrochloride form A in ACN / water (90 / 10, v / v) to obtain Compound 1 hydrochloride form D.

106. A process for preparing the crystalline form of any one of claims 47 to 54, comprising the steps of: a) adding Compound 1 or Compound 1 Form A and fumaric acid to acetone and stirring to obtain Compound 1 fumarate salt Form B; or b) dissolving Compound 1 or Compound 1 Form A in ACN, adding fumaric acid and stirring to obtain Compound 1 fumarate Form B.

107. A process for preparing the crystalline form of any one of claims 55 to 63, comprising the steps of: a) Compound 1 or Compound 1 Form A was dissolved in acetone / H 2 2O (v / v=9 / 1), adding methanesulfonic acid and stirring to obtain Compound 1 mesylate Form C.

108. 77. The process of any one of claims 68 to 76, further comprising adding crystal seeds of the crystalline form of any one of claims 1 to 64 to obtain a desired crystalline form.